OptimizeRx Narrows Q1 Loss and Raises 2026 Revenue Guidance to $95-$100M
OptimizeRx's Q1 revenue fell 10% to $19.8 million while GAAP net loss narrowed to $0.5 million and adjusted EBITDA rose to $3.3 million. It raised 2026 revenue guidance to $95-100 million, refinanced $35 million of debt for annual savings and integrated programmatic EHR ads for DSPs to broaden point-of-care reach.
1. First Quarter Financial Results
OptimizeRx reported Q1 revenue of $19.8 million, down 10% from $21.9 million a year ago. GAAP net loss narrowed to $0.5 million, or $0.03 per share, while adjusted EBITDA rose to $3.3 million and non-GAAP net income reached $2.7 million.
2. Updated Fiscal 2026 Guidance and Debt Refinancing
The company raised its full-year 2026 revenue guidance to $95-100 million while maintaining an adjusted EBITDA outlook of $21-25 million. It refinanced $35 million of debt in a new banking facility, cutting its interest rate by 625 basis points for roughly $1.5 million in annual savings and paid down $2.7 million of principal in Q1.
3. Operating Efficiency and DSP Integration
OptimizeRx launched operational efficiency initiatives expected to save $3 million annually, including $1 million this year, and expanded its EHR network to demand-side platforms. This programmatic integration enables scalable point-of-care ad campaigns and access to authenticated inventory, opening a new channel for future high-growth revenue.